CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
Neuro Central,
New formulation can be co-administered with gastric acid-reducing…
New formulation can be co-administered with gastric acid-reducing…
TUESDAY, Jan. 18, 2022 (HealthDay News) — From 1990 to 2019, the global burden of chronic lymphocytic leukemia (CLL) increased…